Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $6.7 million.

  • Immunome's Change in Accured Expenses rose 13.40% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 107.22%. This contributed to the annual value of $13.6 million for FY2024, which is 2106.84% up from last year.
  • Per Immunome's latest filing, its Change in Accured Expenses stood at $6.7 million for Q3 2025, which was up 988.05% from $619,000 recorded in Q2 2025.
  • Over the past 5 years, Immunome's Change in Accured Expenses peaked at $6.9 million during Q2 2024, and registered a low of -$8.5 million during Q1 2025.
  • Its 3-year average for Change in Accured Expenses is $1.2 million, with a median of $669,000 in 2024.
  • In the last 5 years, Immunome's Change in Accured Expenses surged by 518.53% in 2024 and then plummeted by 1,373.69% in 2025.
  • Immunome's Change in Accured Expenses (Quarterly) stood at $2.1 million in 2023, then slumped by 97.92% to $43,000 in 2024, then grew by 13.40% to $6.7 million in 2025.
  • Its Change in Accured Expenses was $6.7 million in Q3 2025, compared to $619,000 in Q2 2025 and -$8.5 million in Q1 2025.